“…C4‐substituted phthalazin‐1(2 H )‐ones are key structural units ubiquitously found in a number of biologically active compounds displaying diverse pharmacological activities, [1] such as poly‐PARP inhibitor (Olaparib), [1d] histamine H1 receptor antagonist (Azelastine), [1e] aldose reductase inhibitor (Zopolrestat), [1f] Aurora kinase inhibitor, [1g] human A 3 adenosine receptor antagonist [1h] and proteasome inhibitor [1i] (Figure 1), and the nature of substituents present at the C4 positions have an important impact on their pharmacological activities. Accordingly, there has been a long‐standing research interest in the development of efficient methods for the synthesis of these heterocycles, [2,3] and impressive progress has been achieved in access to C4‐(hetero)arylated, [1i,3a–c,f–h,j,l,n–q,u,v] alkylated, [3b,d,e,k,l,u,v] aminated, [1g,3c,i,m,s] alkenylated [3r] and sulfanylated [3t] phthalazin‐1(2 H )‐ones. Recent years have witnessed ever‐growing research efforts within the synthetic community for incorporation of gem ‐difluoromethylene moiety into organic molecules because this group can effectively enhance the biological activities and the physicochemical properties of the parent compounds [4] .…”